No absolutely not. I hope it is a great drug. His hand in everything PCa is bad for the science. He made a huge mistake with the Asentar trial dosing and I don't think he has the best interests of patients at heart. At one time last year he was the lead investigator on 3 very high profile PCa drug trials. One man controlling everything is not good.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.